Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights
Provided By GlobeNewswire
Last update: Mar 3, 2025
Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability
Read more at globenewswire.com11.87
-0.43 (-3.5%)
Find more stocks in the Stock Screener
OCUL Latest News and Analysis
21 days ago - By: Chartmill
